期刊
DRUG AND ALCOHOL DEPENDENCE
卷 165, 期 -, 页码 53-60出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.drugalcdep.2016.05.012
关键词
Hepatitis C virus; People who inject drugs; Reinfection; Sustained viral response; Record linkage
资金
- Scottish Government
Background: Although people who inject drugs (PWID) are an important group to receive Hepatitis C Virus (HCV) antiviral therapy, initiation onto treatment remains low. Concerns over reinfection may make clinicians reluctant to treat this group. We examined the risk of HCV reinfection among a cohort of PWID (encompassing all those reporting a history of injecting drug use) from Scotland who achieved a sustained virological response (SVR). Methods: Clinical and laboratory data were used to monitor RNA testing among PWID who attained SVR following therapy between 2000 and 2009. Data were linked to morbidity and mortality records. Follow-up began one year after completion of therapy, ending on 31st December, 2012. Frequency of RNA testing during follow-up was calculated and the incidence of HCV reinfection estimated. Cox proportional hazards regression was used to examine factors associated with HCV reinfection. Results: Among 448 PWID with a SVR, 277 (61.8%) were tested during follow-up, median 4.5 years; 191 (69%) received one RNA test and 86 (31%) received at least two RNA tests. There were seven reinfections over 410 person years generating a reinfection rate of 1.7/100 py (95% CI 0.7-3.5). For PWID who have been hospitalised for an opiate or injection related cause post SVR(11%), the risk of HCV reinfection was greater [AHR = 12.9, 95% CI 2.2-76.0, p=0.002] and the reinfection rate was 5.7/100 py (95% CI 1.8-13.3). Conclusion: PWID who have been tested, following SVR, for HCV in Scotland appear to be at a low risk of reinfection. Follow-up and monitoring of this population are warranted as treatment is offered more widely. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据